Dr. Reddy’s Revamps Board, Auditors and Senior Leadership in May 12 Governance Push
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr Reddy’s Laboratories ( (RDY) ) has provided an announcement.
On May 12, 2026, Dr. Reddy’s Laboratories’ board approved several governance and leadership changes, reinforcing its oversight structure ahead of upcoming shareholder meetings. The company moved to reappoint former civil servant and policy expert Dr. K.P. Krishnan as an independent director for a second five-year term starting January 7, 2027, subject to shareholder approval, ensuring continuity of regulatory and economic governance expertise on the board.
The board also approved the appointment of AI industry leader Srikanth Velamakanni as an independent director for a five-year term beginning July 1, 2026, broadening its technology and data-driven strategy capabilities. In parallel, Dr. Reddy’s selected Deloitte Haskins & Sells LLP as its proposed statutory auditor for a five-year term from the 42nd to the 47th AGM, reappointed Sagar & Associates as cost auditors for FY 2026-27, and elevated Global Generics India Head Sandeep Khandelwal to senior management and the Management Council effective May 12, 2026, signaling a strengthened focus on governance, audit rigor and domestic generics leadership.
The most recent analyst rating on (RDY) stock is a Buy with a $16.90 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based pharmaceutical company focused on developing, manufacturing and marketing generic medicines and active pharmaceutical ingredients for global markets. Listed in India and on the New York Stock Exchange, the company has a significant presence in generics, branded formulations and emerging markets, with governance practices aligned to Indian and international listing norms.
The group’s operations are overseen by a board with a mix of executive and independent directors, supported by committees covering audit, nomination and governance. Its senior management team spans global generics, specialty and supporting corporate functions, reflecting a diversified yet tightly regulated pharma business model serving patients and healthcare systems worldwide.
Average Trading Volume: 2,375,381
Technical Sentiment Signal: Hold
Current Market Cap: $11.29B
Learn more about RDY stock on TipRanks’ Stock Analysis page.
